Verastem Oncology announced that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG- 3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). RAMP 301 is the confirmatory study required by the U.S. Food and Drug Administration (FDA) for the combination of avutomet in the first half of next year, moving a significant step closer to addressing the treatment of recurrent low- grade serous ovarian cancer (L GSOC). RAMP 301 is The confirmatory study required by theU.S. Food and Drug administration (FDA) for the combined of avutometinib, with defactinib, its FAK inhibitor, for the treatment of all patients with recurrent LGSOC regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy.

Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS pathway-driven tumors as part of its (Raf And Mek Program). Supported by the "Therapeutic Accelerator Award" Verastem Oncology received from PanCAN, the Company is conducting RAMP 205, a Phase 1b/2 clinical trial evaluating avutometinib anddefactinib with gemcitabine/nab-paclitaxel in patients with front-line metastatic pancreatic cancer. The GOG Foundation is committed to maintaining the highest standards in clinical trials development, execution, analysis, and distribution of results.

The GOG Foundation is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, oncology nurses, biostatisticians (including those with expertise in bioinformatics), basic scientists, quality of life experts, data managers, and administrative personnel.